SEMAGLUTIDE IMPROVES LIVER ENZYMES AND FATTY LIVER INDEX IN PATIENTS WITH OBESITY AND CARDIOVASCULAR DISEASE - RESULTS FROM THE SELECT TRIAL

被引：0
|
作者：
Meyhoefer, Sebastian [1 ]
Cariou, Bertrand [2 ]
Cercato, Cintia [3 ]
Colhoun, Helen [4 ]
Deanfield, John [5 ]
Kjaer, Mette Skalshoi [6 ]
Jeppesen, Ole [6 ]
Lincoff, A. Michael [7 ,8 ]
Lingvay, Ildiko [9 ]
Newsome, Phillip [10 ,11 ]
Nicholls, Stephen [12 ]
Pelaez, Maria De Los Angeles Quiroga [6 ]
Santini, Ferruccio [13 ]
Sanyal, Arun [14 ]
Kahn, Steven [15 ,16 ]
机构：
[1] Novo Nordisk Pharma GmbH, Clin Med & Regulatory, Mainz, Germany
[2] Nantes Univ, CHU Nantes, CNRS, INSERM,Inst Thorax, Nantes, France
[3] Univ Sao Paulo, Hosp Clin, Dept Endocrinol, Obes Unit, Sao Paulo, Brazil
[4] Univ Edinburgh, Inst Genet & Canc, Edinburgh, Midlothian, Scotland
[5] UCL, Inst Cardiovasc Sci, London, England
[6] Novo Nordisk AS, Soborg, Denmark
[7] Cleveland Clin, Cleveland, OH 44106 USA
[8] Case Western Reserve Univ, Lerner Coll Med, Cleveland, OH 44106 USA
[9] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[10] Kings Coll London, Inst Hepatol, London, England
[11] Kings Coll Hosp London, London, England
[12] Monash Univ, Victorian Heart Inst, Melbourne, Vic, Australia
[13] Univ Hosp Pisa, Obes & Lipodystrophy Ctr, Pisa, Italy
[14] Virginia Commonwealth Univ, Sch Med, Richmond, VA USA
[15] VA Puget Sound Hlth Care Syst, Seattle, WA USA
[16] Univ Washington, Seattle, WA 98195 USA
来源：
HEPATOLOGY | 2024年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
623
引用
收藏
页码：S457 / S459
页数：3
相关论文
共 50 条
  • [1] Obesity, Cardiovascular Disease, and the Promising Role of Semaglutide: Insights from the SELECT Trial
    Irfan, Hamza
    CURRENT PROBLEMS IN CARDIOLOGY, 2024, 49 (01)
  • [2] Effect of semaglutide on fatty liver disease biomarkers in patients with diabetes and obesity
    Carretero-Gomez, J.
    Carrasco-Sanchez, F. J.
    Fernandez-Rodriguez, J. M.
    Casado-Escribano, P.
    Miramontes-Gonzalez, J. P.
    Segui-Ripoll, J. M.
    Ena, J.
    Arevalo-Lorido, J. C.
    REVISTA CLINICA ESPANOLA, 2023, 223 (03): : 134 - 143
  • [3] Semaglutide Concurrently Improves Vascular and Liver Indices in Patients With Type 2 Diabetes and Fatty Liver Disease
    Korakas, Emmanouil
    Kountouri, Aikaterini
    Pavlidis, George
    Oikonomou, Evangelos
    Vrentzos, Emmanouil
    Michalopoulou, Eleni
    Tsigkou, Vasiliki
    Katogiannis, Konstantinos
    Pliouta, Loukia
    Balampanis, Konstantinos
    Pililis, Sotirios
    Malandris, Konstantinos
    Tsapas, Apostolos
    Siasos, Gerasimos
    Ikonomidis, Ignatios
    Lambadiari, Vaia
    JOURNAL OF THE ENDOCRINE SOCIETY, 2024, 8 (08)
  • [4] Liver Enzymes, Nonalcoholic Fatty Liver Disease, and Incident Cardiovascular Disease
    Targher, Giovanni
    Day, Christopher P.
    HEPATOLOGY, 2011, 53 (01) : 375 - 375
  • [5] Semaglutide Improves Cardiovascular Outcomes in Patients with a History of Coronary Artery Bypass Surgery and Overweight or Obesity: The SELECT Trial
    Verma, Subodh
    Emerson, Scott
    Plutzky, Jorge
    Kahn, Steven
    Stensen, Signe
    Weeke, Peter
    Rasmussen, Soren
    Poirier, Paul
    Lingvay, Ildiko
    Lincoff, Abraham
    CIRCULATION, 2024, 150 (25) : E742 - E743
  • [6] SEMAGLUTIDE, INFLAMMATORY MARKERS AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH OVERWEIGHT OR OBESITY IN THE SELECT TRIAL
    Plutzky, Jorge
    Bogdanski, Pawel
    Dagdelen, Selcuk
    Deanfield, John
    Emerson, Scott
    Hovingh, G.
    Kahn, Steven
    Larsen, Signe
    Latkovskis, Gustavs
    Lehrke, Michael
    Hardt-Lindberg, Soren
    Lingvay, Ildiko
    Nicholls, Stephen
    Oral, Tugce
    Terns, Paula Perez
    Rasmussen, Soren
    Ridker, Paul
    Ryan, Donna
    Lincoff, A. Michael
    ATHEROSCLEROSIS, 2024, 395
  • [7] THE COST-EFFECTIVENESS OF SEMAGLUTIDE 2.4MG IN PATIENTS WITH OVERWEIGHT/OBESITY AND CARDIOVASCULAR DISEASE FROM THE SELECT TRIAL
    McEwan, P.
    Bog, M.
    Faurby, M.
    Foos, V
    Lingvay, I
    Lubker, C.
    Miller, R.
    Toliver, J.
    Yeates, F.
    Lincoff, A. M.
    VALUE IN HEALTH, 2024, 27 (06) : S148 - S148
  • [8] Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
    Colhoun, Helen M.
    Lingvay, Ildiko
    Brown, Paul M.
    Deanfield, John
    Brown-Frandsen, Kirstine
    Kahn, Steven E.
    Plutzky, Jorge
    Node, Koichi
    Parkhomenko, Alexander
    Ryden, Lars
    Wilding, John P. H.
    Mann, Johannes F. E.
    Tuttle, Katherine R.
    Idorn, Thomas
    Rathor, Naveen
    Lincoff, A. Michael
    NATURE MEDICINE, 2024, 30 (07) : 2058 - 2066
  • [9] Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity
    Fracanzani, Anna Ludovica
    Petta, Salvatore
    Lombardi, Rosa
    Pisano, Giuseppina
    Russello, Maurizio
    Consonni, Dario
    Di Marco, Vito
    Camma, Calogero
    Mensi, Laura
    Dongiovanni, Paola
    Valenti, Luca
    Craxi, Antonio
    Fargion, Silvia
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2017, 15 (10) : 1604 - +
  • [10] Effect of semaglutide on kidney outcomes in people with overweight or obesity and established cardiovascular disease in the SELECT trial
    Colhoun, Helen M.
    Lingvay, Ildiko
    Brown, Paul M.
    Deanfield, John
    Brown-Frandsen, Kirstine
    Kahn, Steven E.
    Plutzky, Jorge
    Node, Koichi
    Parkhomenko, Alexander
    Ryden, Lars
    Wilding, John P. H.
    Mann, Johannes F. E.
    Tuttle, Katherine R.
    Idorn, Thomas
    Rathor, Naveen
    Lincoff, A. Michael
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
12345